Literature DB >> 20113972

Biomarkers for tuberculosis disease activity, cure, and relapse.

Robert S Wallis, Cunshan Wang, T Mark Doherty, Phillip Onyebujoh, Mahnaz Vahedi, Hannu Laang, Ole Olesen, Shreemanta Parida, Alimuddin Zumla.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20113972     DOI： 10.1016/S1473-3099(10)70003-7

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  36 in total

Review 1.  The challenge of new drug discovery for tuberculosis.

Authors:  Anil Koul; Eric Arnoult; Nacer Lounis; Jerome Guillemont; Koen Andries
Journal:  Nature       Date:  2011-01-27       Impact factor: 49.962

2.  Suppressed type 1, type 2, and type 17 cytokine responses in active tuberculosis in children.

Authors:  N Pavan Kumar; R Anuradha; R Suresh; R Ganesh; Janani Shankar; V Kumaraswami; Thomas B Nutman; Subash Babu
Journal:  Clin Vaccine Immunol       Date:  2011-09-28

3.  Population pharmacokinetic/pharmacodynamic analysis of the bactericidal activities of sutezolid (PNU-100480) and its major metabolite against intracellular Mycobacterium tuberculosis in ex vivo whole-blood cultures of patients with pulmonary tuberculosis.

Authors:  Tong Zhu; Sven O Friedrich; Andreas Diacon; Robert S Wallis
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

Review 4.  Towards a point-of-care test for active tuberculosis: obstacles and opportunities.

Authors:  Ruth McNerney; Peter Daley
Journal:  Nat Rev Microbiol       Date:  2011-03       Impact factor: 60.633

5.  Comparative proteomic analysis of serum diagnosis patterns of sputum smear-positive pulmonary tuberculosis based on magnetic bead separation and mass spectrometry analysis.

Authors:  Jiyan Liu; Tingting Jiang; Feng Jiang; Dandan Xu; Liliang Wei; Chong Wang; Zhongliang Chen; Xing Zhang; Jicheng Li
Journal:  Int J Clin Exp Med       Date:  2015-02-15

6.  Tuberculosis drug development: ensuring people living with HIV are not left behind.

Authors:  Anne F Luetkemeyer; Haileyesus Getahun; Gabriel Chamie; Christian Lienhardt; Diane V Havlir
Journal:  Am J Respir Crit Care Med       Date:  2011-08-25       Impact factor: 21.405

7.  Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [¹⁸F]2-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.

Authors:  Laura E Via; Dan Schimel; Danielle M Weiner; Veronique Dartois; Emmanuel Dayao; Ying Cai; Young-Soon Yoon; Matthew R Dreher; Robin J Kastenmayer; Charles M Laymon; J Eoin Carny; Joanne L Flynn; Peter Herscovitch; Clifton E Barry
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

8.  Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis.

Authors:  A Jayakumar; E Vittinghoff; M R Segal; W R MacKenzie; J L Johnson; P Gitta; J Saukkonen; J Anderson; M Weiner; M Engle; C Yoon; M Kato-Maeda; P Nahid
Journal:  Tuberculosis (Edinb)       Date:  2015-05-09       Impact factor: 3.131

9.  Strongyloides stercoralis Coinfection Is Associated With Greater Disease Severity, Higher Bacterial Burden, and Elevated Plasma Matrix Metalloproteinases in Pulmonary Tuberculosis.

Authors:  Nathella P Kumar; Gokul R Kathamuthu; Kadar Moideen; Vaithilingam V Banurekha; Dina Nair; Michael P Fay; Thomas B Nutman; Subash Babu
Journal:  J Infect Dis       Date:  2020-08-17       Impact factor: 5.226

10.  Circulating biomarkers of pulmonary and extrapulmonary tuberculosis in children.

Authors:  Nathella Pavan Kumar; R Anuradha; Bruno B Andrade; N Suresh; R Ganesh; Janani Shankar; V Kumaraswami; Thomas B Nutman; Subash Babu
Journal:  Clin Vaccine Immunol       Date:  2013-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.